Cambridge, Massachusetts-based Third Harmonic did not set any financial terms for the stock sale outlined in the preliminary IPO paperwork filed with regulators on Tuesday. However, IPO research firm ...

-- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 The Company is initiating nonclinical studies ...

Third Harmonic Bio is braving the frosty IPO waters. With the weakest quarter for biotech IPOs in years still fresh in the memory, and the proceeds of a $105 million series B still in its bank account ...

Third Harmonic Bio discontinuing its chronic inducible urticaria program after its only asset failed in a phase 1 safety trial paralyzes its clinical pipeline. Shareholders are now waiting on a ...

Third Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolution. What Happened: Third Harmonic announced that its board approved and ...

SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported ...

After San Francisco biotech company Third Harmonic Bio slashed its staff by half in February, it’s now taking a more drastic step. The inflammatory disease research company’s directors have decided to ...